In Vivo Imaging of Mitochondria Structure and Function in Therapy Resistant Lung Tumors
难治性肺肿瘤线粒体结构和功能的体内成像
基本信息
- 批准号:10747207
- 负责人:
- 金额:$ 4.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAmericanAreaBiguanidesBioenergeticsBiological MarkersBiopsyCancer PatientCell LineCell RespirationClassificationClinicalComplexDataDependenceDiagnosisDiagnosticDiseaseDisease ResistanceDissectionElectron TransportEpidermal Growth Factor ReceptorExhibitsFunctional ImagingGene Expression ProfilingGenetically Engineered MouseGoalsHealthHumanImmuno-ChemotherapyImmunotherapyKRAS2 geneKnowledgeLung AdenocarcinomaLung NeoplasmsMaintenanceMalignant neoplasm of lungMeasuresMembrane PotentialsMetabolicMetabolic PathwayMetabolismMitochondriaMutationNon-Small-Cell Lung CarcinomaOncogenicOxidative PhosphorylationPatientsPhenotypePhosphorylation InhibitionPhysiologicalPositron-Emission TomographyRationalizationResearchResistanceResistance developmentSTK11 geneSiteSpirometryStructureSurvival RateTestingTherapeuticTimeTracerTyrosine Kinase InhibitorWorkadvanced diseasecancer therapycheckpoint therapydiagnostic strategydriver mutationfluorodeoxyglucoseimage guidedimaging probeimprovedin vivoin vivo imaginginhibitormetabolic profilemitochondrial membranemitochondrial metabolismmutantnano-stringneoplastic cellnovelnovel diagnosticsnovel strategiesnovel therapeutic interventionnovel therapeuticspatient derived xenograft modelstemsuperresolution microscopytargeted treatmenttherapy developmenttherapy resistanttreatment responsetumortumor initiationtumor metabolismuptake
项目摘要
Abstract
The overarching goal of this study is to identify effective metabolic based diagnostic and therapeutic strategies
to improve the overall survival of patients with Non-small cell lung cancer (NSCLC). We propose to investigate
the positron emission tomography (PET) tracer, 18F-BnTP as a novel metabolic diagnostic and to develop
metabolic based therapeutic strategies targeting oxidative mitochondrial metabolism in therapy resistant
KRAS/LKB1 and EGFR mutant lung tumors. NSCLC will claim the lives of ~130,000 in the US in 2021. Lung
tumors frequently possess a high mutational burden, often rendering single agent therapies targeting
oncogenic driver mutations unsuccessful. Furthermore, metabolically active subsets of lung adenocarcinomas
(LUADs) bearing mutations in KRAS and LKB1 or EGFR are frequently resistant to immunotherapy
approaches. However, regardless of the initials benefits from checkpoint inhibitors or targeted therapies, the
majority of patients will eventually develop resistance to therapy. We rationalize a different approach to
overcoming therapy resistance in NSCLC – namely the classification of tumors by their metabolic signature.
Here, tumors are grouped and targeted by their metabolic dependencies rather than solely by their genetic
alterations. NSCLC is a metabolically heterogeneous disease and tumors utilize both glycolytic and oxidative
mitochondrial metabolism to grow. The mitochondria are the site of cellular bioenergetics and oxidative
phosphorylation (OXPHOS) and are essential for lung tumor initiation and maintenance. Due to a lack of in
vivo imaging probes there is a gap in our knowledge at a physiological and mechanistic level of how
mitochondrial bioenergetics are regulated in NSCLC. To address this gap, we functionally imaged
mitochondrial activity in lung tumors utilizing the PET imaging tracer 18F-BnTP and demonstrate that it
functions an in vivo biomarker of mitochondrial membrane potential (ΔΨ) and oxidative phosphorylation
(OXPHOS) in lung tumors3. Importantly, by using 18F-BnTP PET imaging we are able to distinguish between
OXPHOS dependent and independent lung tumors. Therapeutically, we have demonstrated that 18F-BnTP
positive, OXPHOS-dependent LUADs are sensitive to mitochondrial complex I inhibitors. We hypothesize that
18F-BnTP PET imaging can be utilized to functionally profile mitochondrial bioenergetics and adaptive oxidative
metabolism in therapy-resistant lung tumors to guide treatment with OXPHOS inhibitors. In aim 1 we will
perform an in vivo dissection of mitochondrial bioenergetics in therapy-resistant LUADs. In aim 2 we will
perform a structural and functional in vivo analysis of adaptive oxidative metabolism in therapy-resistant
KRAS/LKB1 and EGFR mutant LUADs. In Aim 3 we will longitudinally profile oxidative metabolism in LUAD
patients with advanced disease. The proposed work has relevance to human health in which we propose that
18F-BnTP PET imaging guided targeting and oxidative metabolism represents a new therapeutic strategy to
overcome therapy resistance in patients with KRAS/LKB1 and EGFR mutant tumors.
抽象的
这项研究的总体目标是确定有效的基于代谢的诊断和治疗策略
提高非小细胞肺癌(NSCLC)患者的总体生存率。我们建议调查
正电子发射断层扫描 (PET) 示踪剂 18F-BnTP 作为一种新型代谢诊断并开发
针对治疗耐药的氧化线粒体代谢的基于代谢的治疗策略
KRAS/LKB1 和 EGFR 突变肺肿瘤。 2021 年,非小细胞肺癌将夺走美国约 130,000 人的生命。 肺癌
肿瘤通常具有高突变负荷,通常需要单药治疗
致癌驱动突变不成功。此外,肺腺癌的代谢活跃亚型
携带 KRAS 和 LKB1 或 EGFR 突变的 (LUAD) 经常对免疫治疗产生耐药性
接近。然而,无论检查点抑制剂或靶向治疗的最初益处如何,
大多数患者最终会对治疗产生耐药性。我们合理化了一种不同的方法
克服非小细胞肺癌的治疗耐药性——即根据肿瘤的代谢特征对肿瘤进行分类。
在这里,肿瘤是根据其代谢依赖性而不是仅仅根据其遗传来分组和靶向的
变更。 NSCLC 是一种代谢异质性疾病,肿瘤同时利用糖酵解和氧化
线粒体代谢生长。线粒体是细胞生物能和氧化的场所
磷酸化(OXPHOS)对于肺肿瘤的发生和维持至关重要。由于缺乏在
体内成像探针在生理和机械层面上我们的知识存在差距
线粒体生物能在 NSCLC 中受到调节。为了解决这一差距,我们对功能进行了成像
利用 PET 成像示踪剂 18F-BnTP 检测肺部肿瘤中的线粒体活性,并证明它
是线粒体膜电位 (ΔΨ) 和氧化磷酸化的体内生物标志物
(OXPHOS)在肺部肿瘤中3。重要的是,通过使用 18F-BnTP PET 成像,我们能够区分
OXPHOS 依赖性和非依赖性肺肿瘤。在治疗上,我们已经证明 18F-BnTP
阳性、OXPHOS 依赖性 LUAD 对线粒体复合物 I 抑制剂敏感。我们假设
18F-BnTP PET 成像可用于功能性分析线粒体生物能学和适应性氧化
耐药性肺部肿瘤的代谢,以指导 OXPHOS 抑制剂的治疗。在目标 1 中,我们将
对治疗抵抗性 LUAD 中的线粒体生物能学进行体内解剖。在目标 2 中,我们将
对治疗耐药的适应性氧化代谢进行结构和功能体内分析
KRAS/LKB1 和 EGFR 突变 LUAD。在目标 3 中,我们将纵向分析 LUAD 中的氧化代谢
患有晚期疾病的患者。拟议的工作与人类健康相关,我们建议
18F-BnTP PET 成像引导靶向和氧化代谢代表了一种新的治疗策略
克服 KRAS/LKB1 和 EGFR 突变肿瘤患者的治疗耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David B Shackelford其他文献
David B Shackelford的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David B Shackelford', 18)}}的其他基金
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
治疗耐药性肺肿瘤线粒体结构和功能的体内成像
- 批准号:
10866660 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
治疗耐药性肺肿瘤线粒体结构和功能的体内成像
- 批准号:
10522994 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
治疗耐药性肺肿瘤线粒体结构和功能的体内成像
- 批准号:
10649562 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
(PQ5) LKB1 突变肺癌线粒体异质性成像
- 批准号:
9750637 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
LKB1 突变肺癌线粒体异质性成像
- 批准号:
9392856 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
LKB1 突变肺癌线粒体异质性成像
- 批准号:
9403002 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
(PQ5) LKB1 突变肺癌线粒体异质性成像
- 批准号:
10063382 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
LKB1 突变肺癌线粒体异质性成像
- 批准号:
10585832 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
相似海外基金
African American (AA) Communities Speak: Partnering with AAs in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care
非裔美国人 (AA) 社区发言:与北部和南部的 AA 合作,培训姑息治疗临床医生,以解决人际和系统性种族主义并提供文化一致的护理
- 批准号:
10734272 - 财政年份:2023
- 资助金额:
$ 4.07万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10541028 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10684239 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10395616 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10786490 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10821849 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10384110 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10336591 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Community-Academic Partnerships to Address COVID-19 Inequities within African American Communities
社区学术伙伴关系解决非裔美国人社区内的 COVID-19 不平等问题
- 批准号:
10245326 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Engaging scientists and communities to address the impacts of substance abuse on American Indian and Alaska Native children and families: The Native Children's Research Exchange Annual Meetings
让科学家和社区参与解决药物滥用对美洲印第安人和阿拉斯加原住民儿童和家庭的影响:原住民儿童研究交流年会
- 批准号:
10657317 - 财政年份:2020
- 资助金额:
$ 4.07万 - 项目类别:














{{item.name}}会员




